Real-life treatment of hypertension in UK primary care: Prescribing habits, results and adherence to clinical guidelines

British Journal of Cardiology

Volumn 10, Issue SUPPL. 3, 2003, Pages

  Duggan, Andrew K ^a   Niziol, Christie J ^a  

^a Decision Resources Group   (United Kingdom)

Author keywords

Antihypertensive agents; Blood pressure; Disease management; Hypertension; Retrospective studies; UK

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY HEALTH CARE; PRIMARY MEDICAL CARE; UNITED KINGDOM;

EID: 0042028578     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995;8:189-92.
2. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-1762.
3. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population. BMJ 1995;311:293-5.
4. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: Results from the Health Survey for England 1998. Hypertension 2001;38:827-32.
5. Feher MD. Hypertension in diabetes. Pract Diabetes Internat 2001;18:197-200.
6. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107:753-6.
7. Grossman E, Messerli FH, Goldbourt U. Review: Intensive blood pressure control and drugs reduce morbidity and mortality in hypertension and diabetes mellitus. Evidence-Based Medicine 2001;6:44-7.
8. Kassianos G. Optimising management of patients with hypertension and diabetes. Br J Cardiol 2002;9:297-302.
9. Brown M, Cruickshank J, Dominiczak A, MacGregor G, Poulter N, Russell G. Better blood pressure control: How to combine drugs. J Hum Hypertens 2003;17:81-6.
10. National Institute for Clinical Excellence. Clinical Guidelines for Type II Diabetes; Blood Pressure Management. Sheffield: Royal College of General Practitioners. Effective clinical practice unit, 2001:1-145.
11. Sever P, Beevers G, Bulpitt C et al. Management guidelines in essential hypertension: Report of the second working party of the British Hypertension Society. BMJ 1993;306:983-7.
12. DIN-Link database: Compufile Ltd. www.compufile.co.uk.
13. Ramsay L, Williams B, Johnston G et al. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.
14. Lip G, Beevers M, Beevers D. The 'Birmingham Hypertension Square' for the optimum choice of add-in drugs in the management of resistant hypertension. J Hum Hypertens 1998;12:761-3.
15. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data. CMAJ 1999;160:41-6.
16. Wogen J, Charles A, Kreilick A, Livornese R, Frech F. A population-based study of compliance and persistency with cardiovascular agents used in hypertension management. Am J Hypertens 2001;14(suppl 1):112a-115a.
17. NSF. National Service Framework for Coronary Heart Disease. London: Department of Health, 2000.